General
The overall environment where patients receive psychedelics is allegedly extremely important, with many possibilities of personalisation: music, paintings, low intensity lights, or the presence of a psychotherapist during the session. Beyond anecdotal experiences, the science behind such proposals and the level of medical evidence supporting these aspects are relatively weak and need more clear descriptions.
Psychedelics have now been tested (usually successfully) in a broad spectrum of psychiatric disorders such as major depressive disorder and resistant depression, anorexia nervosa, OCD, PTSD or alcohol use disorder. This makes it difficult to understand what the real psychiatric target of these drugs is.
The first FENS-EPA webinar aims to understand the present indications of psychedelics, and compare their chances of success (effect-size) in the different indications.
Programme:
Welcome and introduction, Prof. Dirk Schubert
- , Prof. Guy Goodwin
- , Prof. Emma S J Robinson
- , moderated by Prof. Tomáš Páleníček
Date and Location
Costs and registration
Registration is now open! Please note there is a limited number of places (first-come, first-served basis).
Contact
For more information, please visit the website of FENS.
Email: chet@fens.org